Effects of Polymorphisms in Interferon λ 3 (Interleukin 28B) onSustained Virologic Response to Therapy in Patients With Chronic Hepatitis D Virus Infection

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 10, 2014, Pages 1753-1758

  Yilmaz, Emre ^a   Baran, Bulent ^a   Soyer, Ozlem Mutluay ^a   Onel, Mustafa ^a   Onel, Derya ^a   Ormeci, Asli Cifcibasi ^a   Gokturk, Suut ^a   Evirgen, Sami ^a   Akyuz, Filiz ^a   Demir, Kadir ^a   Besisik, Fatih ^a   Kaymakoglu, Sabahattin ^a   Karaca, Cetin ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Chronic Delta Hepatitis; Immune Regulation; Interferon Lambda 3; SNP

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 28B; PEGINTERFERON ALPHA; VIRUS RNA; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DELTA AGENT HEPATITIS; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS DELTA VIRUS; HUMAN; MALE; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; BLOOD; COHORT ANALYSIS; GENETIC POLYMORPHISM; GENETICS; HEPATITIS D, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; RETROSPECTIVE STUDY; STATISTICAL MODEL; TREATMENT OUTCOME; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; MODELS, STATISTICAL; POLYMORPHISM, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84908111464     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.01.043     Document Type: Article

References (20)

1. Fattovich G., Giustina G., Christensen E., et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000, 46:420-426.
2. Degertekin H., Yalcin K., Yakut M., et al. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int 2008, 28:494-498.
3. Rosina F., Pintus C., Meschievitz C., et al. Arandomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology 1991, 13:1052-1056.
4. Farci P., Mandas A., Coiana A., et al. Treatment of chronic hepatitis D with interferon alfa-2a. NEngl J Med 1994, 330:88-94.
5. Farci P., Roskams T., Chessa L., et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004, 126:1740-1749.
6. Karaca C., Soyer O.M., Baran B., et al. Efficacy of peginterferon alpha treatment for 24 months in chronic delta hepatitis and predictors of response. Antivir Ther 2013, 18:561-566.
7. Lange C.M., Zeuzem S. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. JHepatol 2011, 55:692-701.
8. Sonneveld M.J., Wong V.W., Woltman A.M., et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012, 142:513-520.e1.
9. Niro G.A., Smedile A., Andriulli A., et al. The predominance of hepatitis delta virus genotype I among chronically infected Italian patients. Hepatology 1997, 25:728-734.
10. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. JHepatol 1995, 22:696-699.
11. Bahcecioglu I.H., Aygun C., Gozel N., et al. Prevalence of hepatitis delta virus (HDV) infection in chronic hepatitis B patients in eastern Turkey: still a serious problem to consider. JViral Hepat 2011, 18:518-524.
12. Rosina F., Conoscitore P., Cuppone R., et al. Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology 1999, 117:161-166.
13. Sagnelli E., Felaco F.M., Filippini P., et al. Influence of HDV infection on clinical, biochemical and histological presentation of HBsAg positive chronic hepatitis. Liver 1989, 9:229-234.
14. Fattovich G., Boscaro S., Noventa F., et al. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. JInfect Dis 1987, 155:931-935.
15. Thompson A.J., Muir A.J., Sulkowski M.S., et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139:120-129.e18.
16. Suppiah V., Moldovan M., Ahlenstiel G., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41:1100-1104.
17. Montes-Cano M.A., Garcia-Lozano J.R., Abad-Molina C., et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010, 52:33-37.
18. Peng L.J., Guo J.S., Zhang Z., et al. IL28B rs12979860 polymorphism does not influence outcomes of hepatitis B virus infection. Tissue Antigens 2012, 79:302-305.
19. Lampertico P., Vigano M., Cheroni C., et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013, 57:890-896.
20. Kaymakoglu S., Karaca C., Demir K., et al. Alpha interferon and ribavirin combination therapy of chronic hepatitis D. Antimicrob Agents Chemother 2005, 49:1135-1138.